Amgen
Search results
Regeneron is a leading biotechnology company using the power of science to bring new medicines to patients in need. Explore Regeneron's global presence.
Regeneron's goal is to address serious medical conditions, across multiple and diverse therapeutic areas. View our portfolio of FDA-approved medicines here.
Monitor SARS-CoV-2 variants with Regeneron’s COVID-19 Dashboard. Refreshed daily with new genomes and associated patient metadata. Learn how Regeneron is actively working on testing existing medicines and developing new antibodies to combat the COVID-19 pandemic.
Find resources and information geared specifically toward patients and learn about REGENERON's innovative medicines, community support and more.
Learn about the many Regeneron-invented technologies accelerating drug discovery and development such as VelociGene®, VelociMouse®, VelocImmune® and more.
Jan 30, 2024 · Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs. Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline.
Mar 23, 2021 · This definitive Phase 3 outcomes trial in high-risk non-hospitalized COVID-19 patients ("outpatients") met its primary endpoint, showing the investigational REGEN-COV™ (casirivimab with imdevimab) significantly reduced the risk of hospitalization or death by 70% (1,200 mg intravenous [IV]) and 71% (2,400 mg IV) compared to placebo.
